期刊文献+

加替沙星治疗淋病合并沙眼衣原体、解脲支原体感染的临床观察 被引量:2

Clinical study of the efficacy and safety of Gatifloxacin in the treatment of Gonorrhae Co-infected with Chlamydia trachomatis or Ureaplasma Urealyticum
暂未订购
导出
摘要 目的:评价加替沙星治疗单纯性淋病合并沙眼衣原体和(或)解脲支原体感染的疗效与安全性。方法:病例总数72例,随机分为加替沙星组和对照组。加替沙星组35例,加替沙星片400mg,口服,每日1次,疗程10 d;对照组37例,头孢曲松250 mg,一次肌注,多西环素100 mg,口服,一日2次,疗程10 d。结果:加替沙星组和对照组临床有效率分别为91.4%、91.9%,临床痊愈率分别为85.7%8、3.8%;淋球菌(NG)清除率分别为100%、97.3%,沙眼衣原体(CT)阴转率分别为94.1%、88.9%,解脲支原体(UU)清除率分别为84.6%、82.1%,差异均无显著性意义(P>0.05);不良反应发生率分别为5.71%、24.32%(P<0.05),差异有显著性意义。结论:加替沙星治疗单纯性淋病合并沙眼衣原体和(或)解脲支原体感染与常规治疗方案相比,疗效相近,安全性和耐受性良好。
出处 《暨南大学学报(自然科学与医学版)》 CAS CSCD 北大核心 2005年第4期567-569,共3页 Journal of Jinan University(Natural Science & Medicine Edition)
  • 相关文献

参考文献11

二级参考文献34

  • 1应美娟,宋爱清.加替沙星治疗淋病合并沙眼衣原体、解脲支原体感染的临床疗效[J].现代中西医结合杂志,2007,16(23):3324-3325. 被引量:2
  • 2施军,蔡小嫦,谢明,易敏,丛林,伍斌.加替沙星治疗淋病合并沙眼衣原体、解脲支原体感染的临床观察[J].暨南大学学报(自然科学与医学版),2005,26(4):567-569. 被引量:2
  • 3[1]Hosaka M,Yaxue T, Fukuda H, Tomizawa H, et al.In vitro and in vivo antibacterial activities of AM-1 155, a new 6-fluoro-8-methoxy quinolone. Antimicrobial Agents Chemotherapy, 1992;36:2108~2117.
  • 4[2]Wakabayashi E, Mitsuhashi S. In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methyoxy quinolone. Antimicrobial Agents Chemotherapy, 1994;38:594~601.
  • 5[3]Wise R, Brenwald NP, Andrews JM,et al. The activity of the methylpiperazinyl fluoroquinolone CG5501:A comparison with other fluoroquinolones fluoroquinolones. Antimicrobial Chemotherapy, 1997;39:447~452.
  • 6[4]National Committee for Clinical Laboratory Standards. 1998;18.
  • 7[5]Hosaka M,Kinoshita S, Toyama A,et al. Antibacterial Properties of AM-1155, a new 8-methoxy quinolone. Antimicrobial Chemotherapy, 1995; 36:293~301.
  • 8[6]Tanaka M,Takahashi K, Saika T, et al. Development of fluoroquinoloneresistance and mutations involving GyrA and ParC proteins among Neisseria gonorrhoeae in Japan. Urology, 1998; 159:2215~2219.
  • 9[7]Deguchi T, Yasuda M, Nakano M,ea al. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GryA and ParC.Chemotherapy, 1997;43:239~244.
  • 10[8]Nakashima M,Uematsu T,Kosuge K, et al. Single and multiple-dose pharmacolinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrobial Agents Chemotherapy,1995;39:2635~2640.

共引文献231

同被引文献10

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部